Medtech entrepreneurs and investors are awakening to a new reality in venture funding, where exit times are lengthening and returns on investment are falling short. At the recent IN3 meeting in Dublin, a panel of medtech investors discussed how they are adapting their investment strategies to this changing landscape.
With the flow of medtech investment money continuing to shift from early- to late-stage financings, a new reality is emerging for start-ups and the VCs investing in these companies.
For one thing, a US versus EU divide is becoming more apparent: while more VCs in the US are turning...